NIH scientists synthesize drug that limits liver fibrosis in mice

Liver fibrosis is a progressive scarring of the liver brought on by chronic alcoholism, viral hepatitis, obesity or diabetes. The condition could lead to cirrhosis and cancer of the liver. Despite its prevalence, there is no mainstay treatment to prevent scarring.

Now researchers at the National Institutes of Health (NIH) have reported developing a drug that limits liver fibrosis in mice. The findings have been published online in the journal JCI Insight.

The drug was synthesized using the chemical structure of ibipinapant--a brain-penetrating CB-1 receptor antagonist--as the backbone for the drug with two changes to it.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

First they altered the structure to lower the amount that can pass the blood-brain barrier. This avoided any psychiatric side effects that limit the use of the original drug, ibipinapant, in the clinic. Secondly, they added a molecular group that inhibits the molecule iNOS, an enzyme responsible for promoting inflammation.

“Inducible nitric oxide synthase, or iNOS, is an enzyme that has been shown to play a fundamental role in liver fibrosis pathology and is a potential target for fibrosis therapy,” said George Kunos, who heads the study, in an NIH news release. “It is also an important factor in alcoholic liver disease, viral hepatitis, fatty liver disease, and other pathologies that promote liver fibrosis.”

In two well-established models of liver fibrosis, the NIH group found that their compound worked better to reduce fibrosis than using either CB-1 receptor inhibition or iNOS delivery alone.

Preliminary studies in their lab demonstrate no “off target” effects that might give rise to side effects, at least in their animal models. Kunos admits that the compound will need to be further tested in animal models before it's taken forward to clinical trials.

- here is the release
- get the journal abstract

Related Articles:
Intercept shares dazzle after early success of PhIIb liver disease drug trial
Biomarkers spot hep C liver disease

Suggested Articles

Medtronic has moved to acquire Avenu Medical, developers of a minimally invasive method of building the blood vessel access ports.

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.